TB-500 in Sweden: regulatory status 2026

In Sweden, TB-500 holds no marketing authorisation from Läkemedelsverket^[1] and no centralised authorisation from the European Medicines Agency^[2]. Sweden is an EU member state and applies EU pharmaceutical law directly, so both routes apply. The compound's regulatory status has not changed in the twelve months up to July 2026. This page explains what that classification means under Swedish and EU law, what the WADA prohibition adds, what changed (and what did not), and who to contact with follow-up questions.

Medical disclaimer: this article is for educational and journalistic purposes only. It does not constitute medical or legal advice. Regulations change. Verify any claim with the official regulator or a qualified legal adviser before acting on it. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

How Swedish medicines law classifies TB-500

Sweden's primary medicines legislation is the Läkemedelslag (Medicines Act, SFS 2015:1649), which transposes EU Directive 2001/83/EC into national law. The Act uses a functional definition: any substance that is presented as having properties for treating or preventing disease in humans, or that can restore, correct, or modify physiological functions by exerting a pharmacological, immunological, or metabolic action, qualifies as a medicinal product. TB-500 is sold in the grey market with claims of tissue repair, tendon recovery, and angiogenic activity^[4]. Under that functional test, TB-500 vials sold for recovery purposes are medicinal products regardless of whether the label reads 'for research use only.'

Any medicinal product intended for marketing in Sweden must hold either a Läkemedelsverket national authorisation or a centrally granted EU authorisation issued by the European Commission following a positive EMA opinion. TB-500 holds neither. Under the Act, placing an unauthorised medicinal product on the Swedish market is a criminal offence. For the cross-country classification see the TB-500 regulatory status overview.

Läkemedelsverket's position

Läkemedelsverket is Sweden's national medicines regulator, responsible for authorising medicines and supervising their quality, safety, and efficacy. It has issued no authorisation, registration, or marketing licence for TB-500, thymosin beta-4, the WHO-designated international non-proprietary name timbetasin, or the clinical-stage ophthalmic product RGN-259.^[1] No new-drug application has been submitted through the national procedure. Without a submission, Läkemedelsverket has no basis to evaluate the compound.

Läkemedelsverket has not published a specific notice or guidance document addressing TB-500 by name. The compound's status follows automatically from the Act and the EU framework: a substance that meets the functional definition of a medicinal product without a marketing authorisation is an unauthorised medicine. The agency's enforcement division can act against commercial supply, and the Act provides penalties including fines and imprisonment for placing unauthorised medicinal products in circulation.

The special-access route: licensläkemedel

Sweden operates a special-access mechanism called licensläkemedel, which permits a licensed physician to apply to Läkemedelsverket for permission to prescribe a product that is not authorised in Sweden but holds a marketing authorisation in another country. The route is intended for genuine therapeutic gaps where no Swedish-authorised alternative exists for a specific named patient. TB-500 does not qualify: it holds no marketing authorisation in any EU or EEA country, the UK, or the US. There is no authorised reference product anywhere. A clinician cannot lawfully prescribe a product with no reference authorisation, and the licensläkemedel route does not convert an unauthorised research chemical into a prescribable medicine. For a full country-by-country view see TB-500 regulatory status by country.

EMA and EU-level status

The EMA requires that all medicines must be authorised before they can be marketed and made available to patients in the EU^[2]. The EMA medicines register returns no result for thymosin beta-4, TB-500, timbetasin, or RGN-259 under any authorised, withdrawn, or refused status. No European Public Assessment Report (EPAR) exists. No referral or EU-level review procedure has been opened. The EU clinical-trials register contains no listing for a systemic TB-500 or thymosin beta-4 trial in any EU member state for an injury-recovery indication.

The only human trial programme that has used a thymosin beta-4 formulation in Western-standard controlled trials is the RGN-259 ophthalmic solution (RegeneRx Biopharmaceuticals and ReGenTree joint venture), studied for neurotrophic keratopathy and dry eye disease. That programme uses a topical eye-drop formulation, not the subcutaneous injection route common in the grey market, and it has not produced an EMA marketing authorisation.

What changed in the last twelve months

The regulatory status of TB-500 in Sweden and the EU did not change in the twelve months preceding July 2026. Läkemedelsverket issued no new guidance addressing TB-500 specifically. The EMA opened no new procedure for thymosin beta-4. The WADA section S2.3 prohibition, in force since 1 January 2018, continued without amendment.

The development of note in the period was in the United States, not Sweden. The FDA Pharmacy Compounding Advisory Committee was scheduled to review TB-500 (both free-base and acetate forms) alongside six other peptides at its 23 to 24 July 2026 meeting. That committee advises on whether US compounding pharmacies may lawfully prepare specific substances under section 503A. It is a US-only process. Its outcome does not alter Swedish or EU regulatory status and would not change Läkemedelsverket's position.

The 2026 scientific literature continued to explore preclinical applications of thymosin beta-4. A 2026 review in Sports Medicine noted that many unapproved peptides show favourable tissue-repair outcomes in animal models but that rigorous human safety data are scarce^[6]. A separate 2026 review in the American Journal of Sports Medicine concluded that TB-500 and Tβ4 promoted angiogenesis and tissue repair in preclinical models but that human orthopaedic data are lacking^[5]. Neither review changes the regulatory picture.

The WADA prohibition and Swedish sport

Thymosin-beta4 and its derivatives, including TB-500, were added to the WADA Prohibited List under section S2.3 effective 1 January 2018.^[3] The substance is prohibited both in competition and out of competition. TB-500 is a non-Specified Substance under the Code, meaning sanctions start at the higher end of the range: a first violation typically carries a four-year ineligibility period with limited scope for reduction. Anti-doping laboratories are actively testing for TB-500 metabolites in urine and plasma.

Sweden's national anti-doping framework follows the WADA Code. Swedish sports federations across athletics, swimming, weightlifting and other disciplines apply the same prohibited list. Anyone who competes or expects to compete under Swedish or international anti-doping rules should treat TB-500 as a disqualifying substance. The TB-500 peptide page covers the anti-doping history and the comparative position across governing bodies. Athletes with specific questions can contact the Swedish anti-doping organisation (Antidoping Sverige) directly.

What we do not yet know

Several questions remain open. Whether any sponsor will file for a clinical-trial authorisation with Läkemedelsverket or in another EU member state for systemic TB-500 is unknown. No such application had been announced publicly as of July 2026.

The long-term safety profile of subcutaneously injected TB-500 in humans is uncharacterised. No completed Phase 2 or Phase 3 randomised controlled trial covers systemic injection for any soft-tissue injury indication. The only controlled trial data for a Tβ4 product used a topical eye-drop in 18 patients. Separately, some preclinical work has associated thymosin beta-4 with tumour growth promotion in cancer-cell models. Human relevance for chronic systemic use has not been studied.

There is also a label-ambiguity issue the grey market has not resolved. A vial labelled TB-500 may contain either the AC-LKKTETQ heptapeptide (molecular weight approximately 889 daltons) or full-length thymosin beta-4 (approximately 4,963 daltons). Vendors do not consistently specify which molecule is present, and the two differ analytically. No Swedish or EU authority has issued guidance on how to classify one versus the other for medicines-act purposes.

Who to contact with regulatory questions

For questions about whether a specific product holds a marketing authorisation in Sweden, Läkemedelsverket is the authoritative source. The agency's website at lakemedelsverket.se provides a medicines search and a public enquiries contact. Läkemedelsverket can confirm authorisation status but does not provide legal advice on personal situations.

For questions about WADA prohibited-list status in Swedish sport, Antidoping Sverige (the Swedish anti-doping organisation) is the appropriate contact. TB-500 is listed under WADA S2.3 and all Swedish anti-doping programmes follow the same list. For EU-level questions about centralised authorisation, the EMA's publicly searchable medicines register is at ema.europa.eu. For the import rules specific to Sweden see TB-500 import rules in Sweden.

Regulatory disclaimer: this page reflects our understanding of Swedish and EU medicines law as of 2026-07-20. Regulations change. Verify with Läkemedelsverket or qualified legal counsel before making any decision based on this page.